NCT05904496 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05904496
Title	A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	BeiGene
Indications	lung non-small cell carcinoma lung small cell carcinoma renal cell carcinoma hepatocellular carcinoma stomach carcinoma nasopharynx carcinoma cervical cancer esophageal carcinoma melanoma transitional cell carcinoma skin squamous cell carcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer Advanced Solid Tumor Merkel cell carcinoma malignant mesothelioma endometrial carcinoma gastroesophageal adenocarcinoma
Therapies	BGB-30813 BGB-30813 + Tislelizumab
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| AUS

Additional content available in CKB BOOST